Effect of tibolone on glucose and lipid metabolism in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 251-253

  Cagnacci, Angelo ^a,b   Mallus, Elisabetta ^a   Tuveri, Federica ^a   Cirillo, Rocco ^a   Setteneri, Anna Maria ^a   Melis, Gian Benedetto ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; TIBOLONE; TRIACYLGLYCEROL;

ARTICLE; CLINICAL TRIAL; FEMALE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; LIPID METABOLISM; MENOPAUSAL SYNDROME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0031033809     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.1.3645     Document Type: Article

References (26)

1. van der Vies J. 1987 Pharmacological studies with ((7α, 17α)-17 hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) (Org OD14). Maturitas. [Suppl]1: 15-24.
2. Tax L, Goorisen EM, Kicovic PM. 1987 Clinical profile of ORG OD 14. Maturitas. [Suppl]1:3-13.
3. Crona N, Samsioe G, Lindberg U-B, Silfverstolpe G. 1988 Treatment of climacteric complaints with ORG OD 14: a comparative study with oestradiol valerate and placebo. Maturitas. 9:303-308.
4. Rymer J, Chapman MG, Fogelman I, Wilson POG. 1994 A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas. 18:127-133.
5. Lindsay R, McK Hart D, Krazewski A. 1980 Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J. 280:1207-1209.
6. Geusens P, Dequeker J, Gielen J, Schot LPC. 1991 Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas. 13:155-162.
7. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L. 1991 Org OD 14 and the endometrium. Maturitas. 13:243-251.
8. De Aloysio D, Fabiani AG, Mauloni M, Bottiglioni F. 1987 Use of Org OD 14 for the treatment of climacteric complaints. Maturitas. [Suppl]1:49-65.
9. Hardiman P, Nihoyannopoulos P, Kicovic P, Ginsburg J. 1991 Cardiovascular effects of Org OD 14. A new steroidal therapy for climacteric symptoms. Maturitas. 13:235-242.
10. Walker ID, Davidson JF, Richards A, Yates R, McEwan HP. 1985 The effects of the synthetic steroid Org OD 14 on fibrinolysis and blood lipids in menopausal women. Thromb Haemost. 53:303-305.
11. Haenggi W, Riesen W, Birkhauser MH. 1993 Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein (a). Eur J Clin Chem Clin Biochem. 31:645-650.
12. Crona N, Silfverstolpe G, Samsioe G. 1983 A double-blind cross-over study on the effects of Org OD 14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol (Copenh). 102:451-455.
13. Netelbons JC, Siregar-Emck MTW, Schot LPC, van Ginkel FC, Lips P, Leeuwenkamp OR. 1991 Short-term effects of Org OD 14 and 17 β-oestradiol on bone and lipid metabolism in early postmenopausal women. Maturitas. 13:137-149.
14. Farish E, Fletcher CD, Hart DM, Lindsay R, Leggate J. 1984 Org OD 14: long-term effects on serum lipoproteins. Maturitas. 6:297-299.
15. Després J-P, Lamarche B, Mauriége P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. 1996 Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334:952-957.
16. Scheidt-Nave C, Barrett-Connor E, Wingard DL, Cohn BA, Edeinstein SL. 1991 Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol. 133:565-576.
17. Welch S, Gebhart SSP, Bergman RN, Phillips LS. 1990 Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetics subjects. J Clin Endocrinol Metab. 71:1508-1518.
18. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. 1992 Effects of low doses of transdermal 17 β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab. 74:1396-1400.
19. 1993 Report of a meeting of Physiocians, and Scientists, University College London Medical School. Hypertriglyceridaemia and vascular risk. Lancet. 342:781-787.
20. Bruckert E, Turpin G. 1995 Estrogens and progestins in postmenopausal women: influence on lipid parameters and cardiovascular risk. Horm Res. 43:100-103.
21. Hirvonen E, Malkonen M, Manninen V. 1981 Effects of different progestagens on lipoproteins during postmenopausal replacement therapy. N Engl J Med. 304:560-563.
22. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. 1993 A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 60:664-667.
23. Elkind-Hirsch KE, Sherman LD, Malinak R. 1993 Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab. 76:472-475.
24. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. 1993 Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic:progestogenic activity ratios of a steroidal drug (ORG OD 14). J Steroid Biochem Mol Biol. 45:345-351.
25. Thieband D, De Fronzo RA, Jacot E, et al. 1982 Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism. 31:1128-1136.
26. Fehr MD, Cox A, Levy A, Mayne P, Lant AF. 1996 Short term blood pressure and metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes. Br J Obstet Gynaecol. 103:281-283.